Suppr超能文献

使用接种疫苗人群的血清对六种定量 SARS-CoV-2 血清学检测方法进行协调。

Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects.

机构信息

SCVSA Department, University of Parma, 43121 Parma, Italy.

Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy; IRCCS Ospedale San Raffaele, 20158 Milan, Italy.

出版信息

Clin Chim Acta. 2021 Nov;522:144-151. doi: 10.1016/j.cca.2021.08.024. Epub 2021 Aug 20.

Abstract

BACKGROUND AND AIMS

Vaccines, to limit SARS-CoV-2 infection, were produced and reliable assays are needed for their evaluation. The WHO produced an International-Standard (WHO-IS) to facilitate the standardization/comparison of serological methods. The WHO-IS, produced in limited amount, was never tested for reproducibility. This study aims at developing a reproducible and accessible working standard (WS) to complement the WHO-IS.

MATERIALS AND METHODS

Sera from vaccinated individuals were used to produce the WSs. The WHO-IS, the WSs and single serum samples (n = 48) were tested on 6 quantitative serological devices. Neutralization assays were performed for the 48 samples and compared with their antibody titers.

RESULTS

The WS carry an antibody titer 20-fold higher than the WHO-IS. It was reproducible, showed both good linearity and insignificant intra- and inter-laboratory variability. However, the WSs behave differently from the WHO-IS. Analysis of the 48 samples showed that single correlation factors are not sufficient to harmonize results from different assays. Yet, all the devices predict neutralization activity based on the antibody titer.

CONCLUSIONS

A reproducible and highly concentrated WS, specific for IgG against SARS-CoV-2 Spike-glycoprotein was produced. Such characteristics make it particularly suited for the harmonization of commercially available assays and the consequent evaluation of post-vaccinated individuals.

摘要

背景和目的

为了限制 SARS-CoV-2 感染,已经生产出疫苗,并且需要可靠的检测方法来评估它们。世界卫生组织(WHO)制定了一个国际标准(WHO-IS),以促进血清学方法的标准化/比较。该国际标准(WHO-IS)的产量有限,从未进行过可重复性测试。本研究旨在开发一种可重复且易于使用的工作标准(WS),以补充 WHO-IS。

材料和方法

使用接种疫苗个体的血清来生产 WS。在 6 种定量血清学设备上测试了 WHO-IS、WS 和单个血清样本(n=48)。对 48 个样本进行了中和测定,并与其抗体滴度进行了比较。

结果

WS 的抗体滴度比 WHO-IS 高 20 倍。它具有可重复性,显示出良好的线性和不显著的实验室内和实验室间变异性。然而,WS 与 WHO-IS 的行为不同。对 48 个样本的分析表明,单一的相关因素不足以协调来自不同检测方法的结果。然而,所有设备都基于抗体滴度预测中和活性。

结论

生产出一种可重复且高度浓缩的针对 SARS-CoV-2 刺突糖蛋白 IgG 的 WS。这种特性使其特别适合于协调市售检测方法,并对接种疫苗后的个体进行评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c6b/8378065/8eaf5ad97125/gr1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验